While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

A little more than a year after Astellas Pharma won Food and Drug Administration (FDA) approval for geographic atrophy (GA) ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Astellas Pharma is slowing things down in the inaugural consumer-facing marketing blast for eye disease drug Izervay. | ...

Singlera Genomics and Astellas Pharma presented results during the JSOT 2024 Annual Meeting demonstrating that drug-induced ...

The Federal Circuit has vacated a District of Delaware ruling in a patent case which found that patent claims asserted by ...

Astellas is ready to launch its first digital health offering in the US, a toolkit dedicated to providing at-home monitoring ...

In a news packed morning, Japanese drugmaker Astellas Pharma (TYO: 4503) today revealed two regulatory approvals.

Discover Astellas Pharma's innovative patent for a stable pharmaceutical composition, enhancing cancer diagnostics with a unique antibody conjugate and precise formulation.

The US Food and Drug Administration (FDA) has listed Astellas Pharma’s non-invasive digital health solution, DIGITIVA, ...

Astellas Pharma’s claudin 18.2-directed cytolytic antibody has been approved by the European Commission (EC) as part of a first-line combination treatment for a subset of gastric cancer patients.

Daniel Camardo and Joe Whalen will lead business development efforts here for rare disease drug maker Immedica Pharma.